Home/Pipeline/CLD-601

CLD-601

Oncology (undisclosed)

DiscoveryActive

Key Facts

Indication

Oncology (undisclosed)

Phase

Discovery

Status

Active

Company

Calidi Biotherapeutics

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company with a mission to revolutionize the treatment of solid tumors and metastatic cancers through its innovative stem cell-based delivery platforms. The company's core achievement is the development of the RedTail platform, a 'Trojan horse' system that protects oncolytic viruses from immune clearance, enabling systemic administration to target disseminated disease. Its strategy involves advancing a pipeline of candidates, including the lead program CLD-401, through clinical development while exploring the platform's utility in oncology and beyond. Having gone public in 2023, Calidi is positioned to leverage its novel technology in the competitive field of cancer immunotherapy.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Oncology (undisclosed) Drugs

Drug	Company	Phase	Status
Protease Inhibitor Discovery Programs	Medivir	Discovery	Active
Nucleoside/Nucleotide Discovery Programs	Medivir	Discovery	Active
Orion Collaboration Program 1	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 2	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 3	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 4-6 (Extended)	Glykos Finland	Research	Active
ISB 830	Glenmark Pharmaceuticals	Preclinical	Active
TEM-1	Tempus AI	Discovery/Preclinical	Active
TEM-2	Tempus AI	Discovery/Preclinical	Active
TEM-3	Tempus AI	Discovery/Preclinical	Active
TEM-4	Tempus AI	Discovery/Preclinical	Active
TEM-5	Tempus AI	Discovery/Preclinical	Active